<DOC>
	<DOCNO>NCT03094832</DOCNO>
	<brief_summary>This open label , Phase 1/2 study oral ARQ 092 administer patient least 6 year age overgrowth diseases vascular anomaly genetic alteration PI3K/AKT pathway .</brief_summary>
	<brief_title>Study ARQ 092 Patients With Overgrowth Diseases Vascular Anomalies</brief_title>
	<detailed_description>This open label , Phase 1/2 study ARQ 092 administer orally . The primary objective study assess safety ARQ 092 subject ( least 6 year age ) overgrowth diseases vascular anomaly genetic alteration PI3K/AKT pathway . The first cohort receive dose 15 mg/m2 ARQ 092 administer mouth QD morning without food ( 1 hour prior 2 hour meal ) 3 cycle . If drug-related clinically significant toxicity observe 15 mg/m2 , cohort receive 25 mg/m2 QD 3 cycle . If toxicity observe 25 mg/m2 , agreement Sponsor Investigator , dose may escalate 35 mg/m2 3 cycle ( 45 mg total QD ) . For individual subject , treatment continue unacceptable toxicity another discontinuation criterion meet . Subjects , opinion Investigator agreement Sponsor , derive benefit experimental therapy end 6 cycle ( 9 cycle 35 mg/m2 schedule ) allow remain therapy duration benefit maximum time 12 month start beneficial dose . It expect subject receive 3 9 month treatment .</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Proteus Syndrome</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female subject ≥ 6 year old 2 . Overgrowth diseases vascular anomaly document and/or confirm somatic genetic alteration PIK3CA , AKT , PTEN defined/assessed : Measureable segmental overgrowth , currently experience growth , clinical history overgrowth progression Vascular and/or lymphatic overgrowth disease determine clinical ( dermatological ) , image ( e.g. , bidimensional/volumetric MRI , CT , ultrasound ) , histological/cytological criterion 3 . Subjects significant morbidity , poor quality life , disease characterize poor prognosis 4 . No standard systemic therapeutic option available satisfactory response prior experimental local therapy 5 . Signed informed consent , applicable , sign assent 6 . Hemoglobin ( Hgb ) depend age : 69 year male female : ≥ 11.5 g/dL 1017 year female : ≥ 12.0 g/dL 1017 year male : ≥ 12.5 g/dL &gt; 17 year male female : ≥ 10.0 g/dL 7 . Absolute neutrophil count ( ANC ) : ≥ 1.5 x 109/L 8 . Platelet count ≥ 150 x 109/L ( subject Kaposiform Hemangioendotheliomas ( KHE ) Multifocal Lymphangioendotheliomatosis Thrombocytopenia ( MLT ) , platelet count must ≥ 75 x 109/L ) 9 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) /L 10 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN 11 . Serum creatinine depend age : 610 year male female : maximum 0.59 mg/dL 1115 year male female : maximum 1.2 mg/dL &gt; 15 year male female : maximum 1.5 mg/dL 12 . If female childbearing potential , documentation negative pregnancy test require prior enrollment . Sexually active subject ( male female ) must use adequate contraceptive measure study 90 day end treatment 1 . History Type 1 2 uncontrolled diabetes mellitus require regular medication ( metformin oral hypoglycemic agent ) fast glucose ≥ 160 mg/dL ( &gt; 12 year ) ≥ 180 mg/dL ( ≤ 12 year ) screen visit 2 . Grade 2 per NCI CTCAE version 4.03 bad hypercholesterolemia hypertriglyceridemia &gt; 8 % glycated Hgb ( HbA1C ) 3 . Malabsorption syndrome 4 . History myocardial infarction ( MI ) New York Heart Association ( NYHA ) Class IIIV congestive heart failure within 6 month administration first dose ARQ 092 ( MI occur &gt; 6 month first dose ARQ 092 permit ) ; ≥ Grade 2 per NCI CTCAE version 4.03 conduction defect ( e.g. , right leave bundle branch block ) ; leave ventricular ejection fraction ( LVEF ) &lt; 50 % assess echocardiogram/multigated acquisition ( MUGA ) scan 5 . Major surgery , chemotherapy , radiotherapy , immunotherapy within four week first dose ARQ 092 6 . Any experimental systemic therapy purpose treat PROS ( e.g. , sirolimus , everolimus , high dose steroid ) within two week first dose ARQ 092 7 . Previous treatment AKT inhibitor 8 . Concurrent severe uncontrolled illness relate overgrowth diseases 9 . Ongoing active know infection , include human immunodeficiency virus ( HIV ) infection bleed 10 . Psychiatric illness/substance abuse/social situation would limit compliance study requirement 11 . Pregnant breastfeed 12 . Severe hypersensitivity reaction mammilian target rapamycin ( mTOR ) inhibitor ( e.g. , sirolimus , everolimus ) 13 . Insufficient language proficiency subject ( legal guardian ) complete inform consent quality life questionnaires 14 . Inability swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ARQ 092</keyword>
	<keyword>ArQule</keyword>
	<keyword>AKT</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>Overgrowth</keyword>
	<keyword>Congenital malformation</keyword>
</DOC>